Fig. 3: Assessment of LIBRA-seq with ligand blocking. | Nature Biotechnology

Fig. 3: Assessment of LIBRA-seq with ligand blocking.

From: Efficient discovery of SARS-CoV-2-neutralizing antibodies via B cell receptor sequencing and ligand blocking

Fig. 3

a, Predicted neutralizing antibodies were defined as the subset of selected antibodies with negative ACE2 LIBRA-seq scores from experiments 1 (n = 7 antibodies) and 3 (n = 6 antibodies) and all antibodies with high LIBRA-seq scores (>1) for SARS-CoV-2 S from experiment 2 (n = 7 antibodies). The percentage of neutralizing antibodies from the set of predicted neutralizers is shown for each experiment. b, The IC50 values (µg ml–1) for SARS-CoV-2 neutralization by real-time cell analysis (RTCA) with VSV–SARS-CoV-2 (IC50 values for each antibody are shown as single dots) are plotted for the set of predicted neutralizers. The horizontal lines represent the geometric mean for each experiment. Non-neutralizing antibodies are shown as >10 µg ml–1. c, Spearman correlation of ACE2 LIBRA-seq score (x axis) and percent reduction in ACE2 binding to SARS-CoV-2 (y axis) for antibodies from experiments 1 and 3; Spearman r = –0.54, P = 0.017 (two tailed, 95% confidence interval).

Back to article page